var data={"title":"Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Anthony J Lembo, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Paul Rutgeerts, MD, PhD, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 01, 2014.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Peutz-Jeghers syndrome (PJS) is an autosomal dominant syndrome characterized by multiple hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation, and an increased risk of gastrointestinal and nongastrointestinal cancer [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/1-3\" class=\"abstract_t\">1-3</a>].</p><p>This topic will review the genetic basis, clinical manifestations, and diagnosis of PJS. The management of PJS and other familial hamartomatous polyposis syndromes of the gastrointestinal tract (eg, juvenile polyposis, Cowden syndrome, and Bannayan-Riley Ruvalcaba syndrome) are discussed in detail, separately [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=overview-of-colon-polyps\" class=\"medical medical_review\">&quot;Overview of colon polyps&quot;</a> and <a href=\"topic.htm?path=juvenile-polyposis-syndrome\" class=\"medical medical_review\">&quot;Juvenile polyposis syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY AND GENETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Peutz-Jeghers syndrome (PJS) is rare with an estimated prevalence of 1:8000 to 1:200,000 births [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/5\" class=\"abstract_t\">5</a>]. Males and females are equally affected.</p><p>PJS is an autosomal dominant disorder that is most often due to germline mutations in the <em>STK11 </em>(<em>LKB1) </em>gene<em> </em>encoding a serine threonine kinase mapped to chromosome 19p13.3 [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/6-8\" class=\"abstract_t\">6-8</a>]. Germline mutations in <em>STK11,</em> a designated tumor suppressor gene in combination with an acquired genetic defect of the second <em>STK11</em> allele in somatic cells, are responsible for the clinical manifestations of PJS [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/7-10\" class=\"abstract_t\">7-10</a>]. PJS has a high penetrance of over 90 percent by the age of 30 years, but 10 to 20 percent of individuals with PJS have no family history and are presumed to have PJS due to de novo mutations [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/11\" class=\"abstract_t\">11</a>].</p><p><em>STK11 </em>appears to regulate cell polarity, an observation that may be important for explaining how hamartomas develop and the apparent paradox that PJS patients with benign hamartomatous polyps are at increased risk for cancer [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/12,13\" class=\"abstract_t\">12,13</a>]. A traditional theory has been that, for unclear reasons, some hamartomas in patients with PJS proceed on a pathway to malignant transformation. However, an alternative theory suggests that dysregulation of cell polarization leads concurrently to a cancer predisposition while also creating a predisposition for mucosal prolapse [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/14\" class=\"abstract_t\">14</a>]. Mucosal prolapse can lead to the development of polypoid lesions that are histologically similar to hamartomas. Thus, the hamartomas seen in PJS may be an epiphenomenon reflecting disruption of cell polarity pathways, which predisposes simultaneously to mucosal prolapse (and hamartoma formation) and cancer.</p><p>However, mutations in <em>STK11</em> are detected in only 50 to 80 percent of families with PJS, suggesting that there is a second PJS gene locus [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/9,15-18\" class=\"abstract_t\">9,15-18</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The two characteristic manifestations of Peutz-Jeghers syndrome (PJS) are pigmented mucocutaneous macules and multiple hamartomatous gastrointestinal polyps. Individuals with PJS are also at an increased risk for both gastrointestinal and nongastrointestinal cancers.</p><p class=\"headingAnchor\" id=\"H435868361\"><span class=\"h2\">Mucocutaneous pigmentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mucocutaneous pigmented macules (melanin spots) are present in more than 95 percent of individuals with PJS and are caused by pigment-laden macrophages in the dermis. They are typically flat, blue-gray to brown spots 1 to 5 mm in size. These pigmented macules most commonly occur on the lips and perioral region (94 percent), palms of the hands (74 percent), buccal mucosa (66 percent), and soles of the feet (62 percent) (<a href=\"image.htm?imageKey=GAST%2F80815\" class=\"graphic graphic_picture graphicRef80815 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>]. They may also be seen on the nose, perianal area, and genitals, and rarely in the intestines. Mucocutaneous pigmentation usually occurs during the first one to two years of life, increases in size and number over the ensuing years, and finally fades after puberty with the exception of those on the buccal mucosa. Malignant transformation is extremely rare.</p><p>Mucocutaneous pigmented macules in individuals with PJS may be confused for ephelides (freckles). However, ephelides are typically sparse near the nostrils and mouth, are absent at birth, and never appear on the buccal mucosa. The mucocutaneous pigmented macules, although sensitive for PJS, are not specific and may be associated with other syndromes. (See <a href=\"#H435868640\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Hamartomatous polyps</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastrointestinal hamartomatous polyps are present in most patients with PJS. Although polyps most commonly occur in the small bowel (60 to 90 percent) and more specifically in the jejunum, they can be found throughout the gastrointestinal tract including the stomach (15 to 30 percent) and colon (50 to 64 percent) [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Gastrointestinal polyps develop in the first decade of life and most patients become symptomatic between the ages of 10 and 30. Hamartomatous polyps may also occur outside the gastrointestinal tract, including the renal pelvis, urinary bladder, lungs, and nasopharynx.</p><p>Although 50 percent of patients are asymptomatic at the time of diagnosis, individuals with PJS can present with obstruction caused by intussusception or occlusion of the gastrointestinal lumen by the polyp, abdominal pain caused by infarction, acute or chronic rectal bleeding caused by ulceration, or extrusion of the polyp through the rectum. Up to 69 percent of patients experience an intussusception during their lifetime, most often in the small intestine [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/19-22\" class=\"abstract_t\">19-22</a>].</p><p>On gastrointestinal endoscopy, the Peutz-Jeghers (PJ) polyps have no major distinguishing features, and may be sessile, pedunculated, or lobulated. The number of polyps ranges from 1 to more than 20 per segment of bowel, although some patients have solitary lesions. The size of the polyps ranges from 0.1 to more than 5 cm in diameter (<a href=\"image.htm?imageKey=GAST%2F67988\" class=\"graphic graphic_picture graphicRef67988 \">picture 2</a>). On histology, PJ polyps are hamartomas and contain a proliferation of smooth muscle extending into the lamina propria in an arborization-like fashion; the overlying epithelium is normal (<a href=\"image.htm?imageKey=GAST%2F81889%7EGAST%2F69268\" class=\"graphic graphic_picture graphicRef81889 graphicRef69268 \">picture 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/23\" class=\"abstract_t\">23</a>]. Epithelial misplacement involving all the layers of the bowel has been reported in approximately 10 percent of small intestinal polyps in PJS. Epithelial misplacement, possibly due to mechanical forces, may extend into the serosa and be misdiagnosed as a well-differentiated adenocarcinoma.</p><p class=\"headingAnchor\" id=\"H435867567\"><span class=\"h2\">Cancer risk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PJS is associated with an increased risk of gastrointestinal and nongastrointestinal malignancies [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/24-27\" class=\"abstract_t\">24-27</a>]. In a systematic review of 20 observational studies which included 1644 patients with PJS, the reported lifetime risk for any cancer varied between 37 and 93 percent [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/24\" class=\"abstract_t\">24</a>]. The average age of developing a malignancy was 42 years. The most common sites for malignancy were colorectal, followed by breast, stomach, small bowel, and pancreas.</p><p>In a subsequent report of 133 patients with PJS, the cumulative cancer risk at age 40 and 70 years was 20 and 76 percent, respectively, with a cumulative risk of gastrointestinal cancer of 12 and 51 percent, respectively [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/26\" class=\"abstract_t\">26</a>]. The risk of cancer was higher in women as compared with men (hazard ratio 4.8, 95% CI 2.8-8.0). During 5004 person-years of follow-up there were 42 deaths, occurring at a mean age of 45 years. Two-thirds of the deaths were cancer-related. An Italian collaborative study of 119 patients with PJS reported similar rates of cancer [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H435867590\"><span class=\"h3\">Gastrointestinal cancers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with PJS have an estimated lifetime risk of gastrointestinal cancer of 38 to 66 percent [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/24\" class=\"abstract_t\">24</a>]. The lifetime cancer risk by organ site is as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Colorectal &ndash; 39 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stomach &ndash; 29 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Small bowel &ndash; 13 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pancreas &ndash; 11 to 36 percent</p><p/><p>Other gastrointestinal tumors that have been associated with PJS include cancers of the biliary tree, gallbladder, and esophagus [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/26,28,29\" class=\"abstract_t\">26,28,29</a>].</p><p>The distribution of gastrointestinal cancers in PJS is similar to that of the hamartomatous polyps and carcinoma arising in hamartomas has been clearly documented [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/30-33\" class=\"abstract_t\">30-33</a>]. The reason for the increased risk of gastrointestinal cancer is uncertain, but does not appear to be due to increased oncogene expression, known to be involved in the adenoma-carcinoma sequence in colorectal cancer [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]. (See <a href=\"#H2\" class=\"local\">'Epidemiology and genetics'</a> above and <a href=\"topic.htm?path=molecular-genetics-of-colorectal-cancer\" class=\"medical medical_review\">&quot;Molecular genetics of colorectal cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H435867596\"><span class=\"h3\">Nongastrointestinal cancers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of nongastrointestinal cancers is also increased in individuals with PJS [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/35,36\" class=\"abstract_t\">35,36</a>]. In a meta-analysis of six studies that included 210 individuals with PJS, extracolonic cancers accounted for 55 of the 66 malignancies (83 percent) between the ages of 15 and 64 years [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/29\" class=\"abstract_t\">29</a>]. As compared with population-based controls, the risk was increased for cancers of the lung, breast, uterus, and ovary.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Women have an increased lifetime risk of gynecological cancers (13 to 18 percent) [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/24\" class=\"abstract_t\">24</a>]. Specifically, women with PJS have an increased lifetime risk for cancers of the breast (32 to 54 percent), ovary (21 percent), and cervix (10 percent). Cervical tumors include cervical adenoma malignum, a highly differentiated mucinous adenocarcinoma with a highly aggressive behavior [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/37\" class=\"abstract_t\">37</a>]. In addition, small, asymptomatic, benign ovarian tumors known as &quot;sex-cord&quot; tumors with annular tubules (SCTAT tumors) occur commonly in women with PJS [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/38,39\" class=\"abstract_t\">38,39</a>]. These tumors are often associated with signs of hyperestrogenism, which can lead to sexual precocity [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/38,39\" class=\"abstract_t\">38,39</a>]. (See <a href=\"topic.htm?path=sex-cord-stromal-tumors-of-the-ovary-granulosa-stromal-cell-tumors\" class=\"medical medical_review\">&quot;Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Men with PJS have an increased lifetime risk of Sertoli cell testicular tumors (9 percent) [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/24,36,40\" class=\"abstract_t\">24,36,40</a>]. While these tumors are often hormonally active, some present with gynecomastia, rapid growth, and advanced bone age with markedly elevated levels of estradiol [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors#H22\" class=\"medical medical_review\">&quot;Anatomy and pathology of testicular tumors&quot;, section on 'Sertoli cell tumors'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H435868693\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A clinical diagnosis of Peutz-Jeghers syndrome (PJS) requires the presence of any <strong>one</strong> of the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two or more histologically confirmed Peutz-Jeghers (PJ) polyps</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Any number of PJ polyps detected in an individual who has a family history of PJS in a close relative</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Characteristic mucocutaneous pigmentation in an individual who has a family history of PJS in a close relative</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Any number of PJ polyps in an individual who also has characteristic mucocutaneous pigmentation</p><p/><p>Individuals who meet clinical criteria for PJS should undergo genetic testing for a germline mutation in the <em>STK11</em> gene. Genetic testing in an individual who meets clinical criteria for PJS serves to confirm the diagnosis of PJS and counsel at-risk family members. However, not all mutations associated with PJS have been identified [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>]. Thus, if no pathogenic <em>STK11</em> mutation is found in an individual who meets clinical criteria for PJS and there is no known mutation of PJS in the family, this does not exclude the diagnosis of PJS. Such individuals and their at-risk relatives still require frequent endoscopic surveillance for removal of polyps throughout the gastrointestinal tract and screening for extraintestinal cancers. (See <a href=\"#H2\" class=\"local\">'Epidemiology and genetics'</a> above and <a href=\"topic.htm?path=juvenile-polyposis-syndrome#H426436025\" class=\"medical medical_review\">&quot;Juvenile polyposis syndrome&quot;, section on 'Cancer screening'</a>.)</p><p>On the contrary, if genetic testing is performed and a mutation is found in an affected individual, then genetic testing of at-risk relatives will provide true positive or negative test results. At-risk members who receive true negative test results have a risk of cancer similar to that of the general population. At-risk relatives who test positive should follow the surveillance guidelines for individuals with PJS. A detailed list of laboratories performing genetic testing can be obtained through the web site <a href=\"http://www.genetest.org/&amp;token=7+GJrCvx/pgnT2Hm8UDNmJoRILKi70Ss3vvVaXV2sxWvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=2533\" target=\"_blank\" class=\"external\">www.genetest.org</a>.</p><p class=\"headingAnchor\" id=\"H435868640\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Peutz-Jeghers syndrome (PJS) can be differentiated from other disorders that may present with pigmented mucocutaneous macules or multiple hamartomatous gastrointestinal polyps based on the clinical presentation <span class=\"nowrap\">and/or</span> genetic testing.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hamartomatous polyps of the small intestine can be associated with Cowden syndrome, Bannayan-Riley Ruvalcaba syndrome (BRRS), and juvenile polyposis syndrome (JPS). BRRS is characterized by macrocephaly, lipomas, vascular abnormalities, and developmental delay. Cowden syndrome has characteristic skin and oral findings including trichilemmomas, acral keratoses, and facial <span class=\"nowrap\">papules/oral</span> papillomas. Pigmented spots in BRRS and Cowden syndrome characteristically occur on the glans penis in males and not on the lips as seen in PJS. Unlike PJS, which is associated with germline mutations in the <em>STK11</em> gene, Cowden syndrome and BRRS are associated with germline mutations in <em>PTEN1</em>.</p><p/><p class=\"bulletIndent1\">JPS is characterized by multiple gastrointestinal juvenile polyps (hamartomas) but is not associated with mucocutaneous pigmentation, which is associated with PJS. JPS is associated with germline mutations in <em>SMAD4, BMPR1A</em>, and <em>ENG</em> genes and not <em>STK11</em> as seen in patients with PJS. (See <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome#H462459902\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;, section on 'Cowden syndrome'</a> and <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome#H462460023\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;, section on 'Bannayan-Riley-Ruvalcaba syndrome'</a> and <a href=\"topic.htm?path=juvenile-polyposis-syndrome\" class=\"medical medical_review\">&quot;Juvenile polyposis syndrome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mucocutaneous pigmentation may be associated with Laugier-Hunziker syndrome (LHS). LHS is an acquired, sporadic, benign disorder that is characterized by intraoral hyperpigmentation on the lips, hard and soft palate, and buccal mucosa. Approximately 60 percent of patients with LHS also have longitudinal hyperpigmented bands on the fingernails and toenails without associated nail dystrophy [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/42\" class=\"abstract_t\">42</a>]. Unlike pigmentation in PJS, which occurs in the first few years of life, LHS lesions are progressively acquired in young or middle-age adults. In addition, LHS is not associated with hamartomatous gastrointestinal polyps or a pathogenic mutation in the <em>STK11</em> gene. (See <a href=\"topic.htm?path=congenital-and-inherited-hyperpigmentation-disorders#H75796009\" class=\"medical medical_review\">&quot;Congenital and inherited hyperpigmentation disorders&quot;, section on 'Peutz-Jeghers syndrome'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Screening and surveillance in individuals with Peutz-Jeghers syndrome (PJS) is discussed in detail, separately. (See <a href=\"topic.htm?path=juvenile-polyposis-syndrome#H426436025\" class=\"medical medical_review\">&quot;Juvenile polyposis syndrome&quot;, section on 'Cancer screening'</a>.)</p><p class=\"headingAnchor\" id=\"H1623647421\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hereditary-colorectal-cancer-syndromes\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Hereditary colorectal cancer syndromes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peutz-Jeghers syndrome (PJS) is an autosomal dominant syndrome characterized by multiple hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation, and an increased risk of gastrointestinal and nongastrointestinal cancer. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PJS is associated with germline mutations in the <em>STK11 </em>(<em>LKB1) </em>gene<em> </em>encoding a serine threonine kinase mapped to chromosome 19p13.3. PJS is rare, with prevalence estimates ranging between 1:8000 and 1:200,000 births. (See <a href=\"#H2\" class=\"local\">'Epidemiology and genetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are two main clinical manifestations of PJS: pigmented mucocutaneous macules and multiple gastrointestinal polyps. (See <a href=\"#H3\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The characteristic mucocutaneous pigmentations (melanin spots) of PJS are present in more than 95 percent of patients, occurring most commonly on the lips and perioral region, palms of the hands, buccal mucosa, and soles of the feet.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Gastrointestinal hamartomatous polyps are present in most patients with PJS and can occur anywhere in the gastrointestinal tract. Polyps develop in the first decade of life and most patients become symptomatic between the age of 10 and 30 years. The number of polyps ranges from 1 to more than 20 per segment of bowel.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PJS is associated with an increased risk of gastrointestinal and nongastrointestinal cancers. The lifetime risk of cancer ranges between 37 and 93 percent, with an average age of 42 years at cancer diagnosis. The most common sites of gastrointestinal tract malignancy are the colon and pancreas, and the most common site of extraintestinal tract cancer is the breast. Women are also at increased risk for cervical tumors including cervical adenoma malignum and benign ovarian tumors known as &quot;sex-cord&quot; tumors with annular tubules (SCTAT tumors). Men with PJS have an increased lifetime risk of Sertoli cell testicular tumors. (See <a href=\"#H435867567\" class=\"local\">'Cancer risk'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A clinical diagnosis of PJS requires the presence of any <strong>one</strong> of the following:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Two or more histologically confirmed Peutz-Jeghers (PJ) polyps</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Any number of PJ polyps detected in an individual who has a family history of PJS in a close relative</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Characteristic mucocutaneous pigmentation in an individual who has a family history of PJS in a close relative</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Any number of PJ polyps in an individual who also has characteristic mucocutaneous pigmentation</p><p class=\"bulletIndent1\"><br/>Individuals who meet clinical criteria for PJS should undergo genetic testing for a mutation in the <em>STK11</em> gene. Genetic testing in an individual who meets clinical criteria for PJS serves to confirm the diagnosis of PJS. However, the absence of a pathogenic <em>STK11</em> mutation in an individual who meets clinical criteria for PJS does not exclude the diagnosis of PJS. (See <a href=\"#H435868693\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PJS can be differentiated from other disorders with pigmented mucocutaneous macules or multiple hamartomatous gastrointestinal polyps based on the clinical manifestations <span class=\"nowrap\">and/or</span> genetic testing. (See <a href=\"#H435868640\" class=\"local\">'Differential diagnosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">JEGHERS H, McKUSICK VA, KATZ KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med 1949; 241:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Peutz JL. Over een zeer merkwaardige, gecombineerde familiaire pollyposis van de sligmliezen van den tractus intestinalis met die van de neuskeelholte en gepaard met eigenaardige pigmentaties van huid-en slijmvliezen. Ned Maandschr v Gen 1921; 10:134.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">JEGHERS H, McKUSICK VA, KATZ KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med 1949; 241:993, illust; passim.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Harned RK, Buck JL, Sobin LH. The hamartomatous polyposis syndromes: clinical and radiologic features. AJR Am J Roentgenol 1995; 164:565.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90:1039.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Olschwang S, Markie D, Seal S, et al. Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet 1998; 35:42.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18:38.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391:184.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Lim W, Hearle N, Shah B, et al. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 2003; 89:308.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Boudeau J, Sapkota G, Alessi DR. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett 2003; 546:159.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Hernan I, Roig I, Martin B, et al. De novo germline mutation in the serine-threonine kinase STK11/LKB1 gene associated with Peutz-Jeghers syndrome. Clin Genet 2004; 66:58.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Baas AF, Kuipers J, van der Wel NN, et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004; 116:457.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Martin SG, St Johnston D. A role for Drosophila LKB1 in anterior-posterior axis formation and epithelial polarity. Nature 2003; 421:379.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Jansen M, de Leng WW, Baas AF, et al. Mucosal prolapse in the pathogenesis of Peutz-Jeghers polyposis. Gut 2006; 55:1.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Volikos E, Robinson J, Aittom&auml;ki K, et al. LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet 2006; 43:e18.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Mehenni H, Gehrig C, Nezu J, et al. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 1998; 63:1641.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Hearle N, Lucassen A, Wang R, et al. Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp and STK11-negative PJS cases. Genes Chromosomes Cancer 2004; 41:163.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">Wang HH, Xie NN, Li QY, et al. Exome sequencing revealed novel germline mutations in Chinese Peutz-Jeghers syndrome patients. Dig Dis Sci 2014; 59:64.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">Utsunomiya J, Gocho H, Miyanaga T, et al. Peutz-Jeghers syndrome: its natural course and management. Johns Hopkins Med J 1975; 136:71.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Hinds R, Philp C, Hyer W, Fell JM. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr 2004; 39:219.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">van Lier MG, Mathus-Vliegen EM, Wagner A, et al. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines? Am J Gastroenterol 2011; 106:940.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Cunningham JD, Vine AJ, Karch L, Aisenberg J. The role of laparoscopy in the management of intussusception in the Peutz-Jeghers syndrome: case report and review of the literature. Surg Laparosc Endosc 1998; 8:17.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Haggitt RC, Reid BJ. Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol 1986; 10:871.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105:1258.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Lim W, Olschwang S, Keller JJ, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004; 126:1788.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">van Lier MG, Westerman AM, Wagner A, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2011; 60:141.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Resta N, Pierannunzio D, Lenato GM, et al. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. Dig Liver Dis 2013; 45:606.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Rebsdorf Pedersen I, Hartvigsen A, Fischer Hansen B, et al. Management of Peutz-Jeghers syndrome. Experience with patients from the Danish Polyposis Register. Int J Colorectal Dis 1994; 9:177.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Perzin KH, Bridge MF. Adenomatous and carcinomatous changes in hamartomatous polyps of the small intestine (Peutz-Jeghers syndrome): report of a case and review of the literature. Cancer 1982; 49:971.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Settaf A, Mansori F, Bargach S, Saidi A. [Peutz-Jeghers syndrome with carcinomatous degeneration of a duodenal hamartomatous polyp]. Ann Gastroenterol Hepatol (Paris) 1990; 26:285.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Defago MR, Higa AL, Campra JL, et al. Carcinoma in situ arising in a gastric hamartomatous polyp in a patient with Peutz-Jeghers syndrome. Endoscopy 1996; 28:267.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Bujanda L, Beguiristain A, Villar JM, et al. [Gastric adenocarcinoma in hamartomatous polyp in Peutz-Jeghers syndrome]. Gastroenterol Hepatol 1996; 19:452.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Entius MM, Westerman AM, Giardiello FM, et al. Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations. Gut 1997; 41:320.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987; 316:1511.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998; 128:896.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Srivatsa PJ, Keeney GL, Podratz KC. Disseminated cervical adenoma malignum and bilateral ovarian sex cord tumors with annular tubules associated with Peutz-Jeghers syndrome. Gynecol Oncol 1994; 53:256.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Young RH, Dickersin GR, Scully RE. A distinctive ovarian sex cord-stromal tumor causing sexual precocity in the Peutz-Jeghers syndrome. Am J Surg Pathol 1983; 7:233.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Young RH, Welch WR, Dickersin GR, Scully RE. Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix. Cancer 1982; 50:1384.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Wilson DM, Pitts WC, Hintz RL, Rosenfeld RG. Testicular tumors with Peutz-Jeghers syndrome. Cancer 1986; 57:2238.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Young S, Gooneratne S, Straus FH 2nd, et al. Feminizing Sertoli cell tumors in boys with Peutz-Jeghers syndrome. Am J Surg Pathol 1995; 19:50.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Kemmett D, Ellis J, Spencer MJ, Hunter JA. The Laugier-Hunziker syndrome--a clinical review of six cases. Clin Exp Dermatol 1990; 15:111.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2533 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY AND GENETICS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H435868361\" id=\"outline-link-H435868361\">Mucocutaneous pigmentation</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Hamartomatous polyps</a></li><li><a href=\"#H435867567\" id=\"outline-link-H435867567\">Cancer risk</a><ul><li><a href=\"#H435867590\" id=\"outline-link-H435867590\">- Gastrointestinal cancers</a></li><li><a href=\"#H435867596\" id=\"outline-link-H435867596\">- Nongastrointestinal cancers</a></li></ul></li></ul></li><li><a href=\"#H435868693\" id=\"outline-link-H435868693\">DIAGNOSIS</a></li><li><a href=\"#H435868640\" id=\"outline-link-H435868640\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">MANAGEMENT</a></li><li><a href=\"#H1623647421\" id=\"outline-link-H1623647421\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2533|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/80815\" class=\"graphic graphic_picture\">- Peutz-Jeghers oral lesions</a></li><li><a href=\"image.htm?imageKey=GAST/67988\" class=\"graphic graphic_picture\">- Peutz Jeghers colonic polyp</a></li><li><a href=\"image.htm?imageKey=GAST/81889\" class=\"graphic graphic_picture\">- PJS duodenal polyp Light</a></li><li><a href=\"image.htm?imageKey=GAST/69268\" class=\"graphic graphic_picture\">- PJS colonic polyp Light</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors\" class=\"medical medical_review\">Anatomy and pathology of testicular tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-and-inherited-hyperpigmentation-disorders\" class=\"medical medical_review\">Congenital and inherited hyperpigmentation disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=juvenile-polyposis-syndrome\" class=\"medical medical_review\">Juvenile polyposis syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecular-genetics-of-colorectal-cancer\" class=\"medical medical_review\">Molecular genetics of colorectal cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-colon-polyps\" class=\"medical medical_review\">Overview of colon polyps</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">PTEN hamartoma tumor syndrome, including Cowden syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sex-cord-stromal-tumors-of-the-ovary-granulosa-stromal-cell-tumors\" class=\"medical medical_review\">Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hereditary-colorectal-cancer-syndromes\" class=\"medical medical_society_guidelines\">Society guideline links: Hereditary colorectal cancer syndromes</a></li></ul></div></div>","javascript":null}